Global tobacco experts issue stark warning that the world is on brink of turning into an 'ashtray planet' that will significantly escalate chronic respiratory diseases
Twenty leading tobacco-control experts contributed to first-of-its-kind report visualising possible 2040 futures around nicotine consumption impact on diseases like asthma and COPD
Report warns world could steer towards doomsday 'ashtray planet' scenario shrouded in second-hand smoke smog, with healthcare systems stretched to limits
It calls for immediate action from health decision makers to persevere with generational bans, restrict nicotine to prescription only, and ban vape flavours or attractive packaging
COPENHAGEN, Denmark, May 30, 2025 /PRNewswire/ -- The Copenhagen Institute for Futures Studies (CIFS), an independent non-profit think tank, gathered twenty tobacco-control specialists from Africa, Europe, the Middle East, North America, South America, and Southeast Asia, to explore four plausible futures to 2040 around nicotine use and the impact this will have on chronic respiratory diseases.
Findings from the experts have been published in a first-of-its-kind report to analyse how tobacco and nicotine use could intersect chronic respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma. The report highlights four possible scenarios for 2040 depending on actions government, health decision makers and individuals take now around nicotine use.
The experts were gathered to explore potential future scenarios and to highlight a course toward one 'endgame generation' scenario we must strive to significantly reduce nicotine use and improve chronic respiratory disease outcomes. At the same time, they also identified tipping points, which closely reflect the current geopolitical climate that risk steering the world to the worst-case scenario the experts deemed 'ashtray planet' by 2040.
In the 'ashtray planet' scenario, tobacco and nicotine use has become deeply entrenched across much of the world. Second-hand smoke and aerosol are common in public spaces with people smoking on public transport, outside hospitals, or even in parks where children play. People begin wearing masks again, not for viruses, but to cope with outdoor smoke and smog.
COPD and asthma become significantly more prevalent stretching health systems to the limit, not to mention the mental health burden on both patients and their caregivers. Health care professionals do little more than renew basic prescriptions, driving a revolving door of readmissions. A surge in undiagnosed asthma leads to attacks with often fatal consequences that could have been prevented among children, disproportionately affecting those in low and middle-income countries.
Aron Szpisjak, Head of Health and Futurist at CIFS said: "Chronic respiratory diseases like asthma and COPD affect 550 million adults yet they are almost invisible in global health discussions. Tobacco is the leading preventable risk factor for these conditions, contributing to 8.3 million deaths every year."
"With the risk of governments catering to corporate interests and economic survival dominating national agendas, what we saw as the doomsday scenario now feels dangerously close to being realised. We still have time to shape the future and steer us on the right course to an endgame where nicotine consumption is reduced significantly, and chronic respiratory diseases begin to decline. We already have the solutions to get us there and avert the ashtray planet scenario. But that can only happen if decision makers across the world commit to sustained, coordinated action."
The report describes early warning signals, policy shifts and trends which could indicate the 'ashtray planet' scenario is beginning to unfold and underscores the urgency for action. For example, when more immediate crises such as economic instability, authoritarian politics, worsening environmental disasters, and mounting inequality lead governments to prioritise economic survival over public health resulting in rollbacks of tobacco-control regulations. Another example is the rise of newer nicotine products such as e-cigarettes, which rapidly gain popularity through social media and celebrity influence, particularly among young people.
Chronic respiratory diseases impose a significant burden, particularly in low- and middle-income countries, where 90% of premature deaths occur due to underdiagnosis and limited access to care.
In the scenario most closely resembling a status quo where developed countries do enact strong tobacco-control policies and uptake of new nicotine products is limited, the report highlights that positive outcomes may remain uneven. This is particularly the case in underserved regions where public trust in government and health institutions is low and there are varying abilities to adapt policies to local realities.
Bogi Eliasen, CIFS Fellow and Futurist , said: "High smoking rates jeopardise our progress towards the Sustainable Development Goal of aiming to reduce premature mortality from non-communicable diseases. While smoking rates are dropping, progress is slow and insufficient. Delaying action further risks slowing progress, making tobacco use harder to reverse, and missing a critical opportunity to protect millions of people."
"We have seen positive signs with the recent approval of the Integrated Lung Health resolution at the World Health Assembly, but there is still work to be done to ensure chronic respiratory diseases maintain priority status. As world leaders gather at the United Nations General Assembly in September this year to adopt a new declaration on non-communicable diseases later this year, they must take strong action on tobacco control and ensure people living with chronic respiratory diseases are meaningfully included in the commitments."
The report includes strategic actions for policy makers, public health bodies, and patient and advocacy groups. Immediate priorities include strengthening tobacco control by persevering with action such as generational bans, restricting new nicotine products to prescription only access, and limiting appeal by banning flavours and attractive packaging.
The full report is available online: https://www.cifs.dk/read-listen/reports-knowledge/the-future-of-chronic-respiratory-diseases-and-nicotine-consumption
Notes to Editors
About the report
The Future of Chronic Respiratory Diseases (CRDs) and Nicotine Consumption: Beyond Smoke and Mirrors report was developed in a two-phase approach. The first phase combined desk research and expert interviews to generate the evidence base, complemented with an AI model built by the CIFS team which included 4,000 peer-reviewed articles and policy documents. To ensure the integrity of the evidence base, studies linked to the tobacco industry were excluded.
The second phase comprised two co-creation workshops that convened more than 20 tobacco-control specialists from Africa, Europe, the Middle East, North America, South America, and Southeast Asia. Participants were selected both for the relevance of their expertise and to ensure a diversity of viewpoints. In the first workshop, the experts identified critical uncertainties to structure the four future scenarios. In workshop two, participants revisited the four draft scenarios to explore early warning signs and tipping points suggesting that a particular trajectory is beginning to unfold, and the strategic trade-offs stakeholders may face.
This report was commissioned by Sanofi and Regeneron. CIFS independently conducted the research, expert interviews, workshop facilitation, and the development of all scenarios and recommendations. While Sanofi and Regeneron provided financial support, CIFS maintained full editorial independence.
Neither the Copenhagen Institute for Futures Studies nor Sanofi and Regeneron have any affiliation with the tobacco or nicotine industry.
About the Copenhagen Institute for Futures Studies (CIFS)
The Copenhagen Institute for Futures Studies is an independent, non-profit think tank established in 1969, on the initiative by former Danish Minister and OECD Secretary-General Professor Thorkil Kristensen.
Our purpose is to help people and organisations imagine, work with, and shape their future. We do this by applying our unique approach to futures studies and foresight, combined with more than 50 years of global experience and contributions to the field, working with organisations across the public, private, academic, and civic sectors, as well as with the general public. Being independent of commercial and political interests enables an objective approach and allows for all profits to go exclusively to fund further research and non-profit initiatives.
Logo - https://mma.prnewswire.com/media/2699222/CIFS_logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/global-tobacco-experts-issue-stark-warning-that-the-world-is-on-brink-of-turning-into-an-ashtray-planet-that-will-significantly-escalate-chronic-respiratory-diseases-302469456.html
SOURCE Copenhagen Institute for Futures Studies (CIFS)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target CHICAGO, June 1, 2025 /PRNewswire/ -- Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy. These first data on pasritamig, from the first-in-human study, demonstrate that pasritamig appears well-tolerated and exhibits a promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.1 These data were presented as an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology. Pasritamig is a novel T-cell engager designed to bind both CD3 on T-cells and KLK2—a prostate-specific antigen with minimal expression outside of the prostate. Pasritamig activates T-cells by binding to CD3 and directing them to KLK2- expressing tumor cells, engaging the body's immune system to specifically target these cancerous cells. This differentiated approach aims to deliver a targeted treatment for patients with advanced prostate cancer, while potentially reducing the high-grade toxicities historically associated with T-cell engagers. "These first-in-human results for pasritamig are highly encouraging, demonstrating that KLK2 is a viable target for T-cell engagers in metastatic castration-resistant prostate cancer," said Capucine Baldini*, M.D., Ph.D., Drug Development Department (DITEP), Institut Gustave Roussy, and presenting author. "The data show a promising safety profile, with manageable adverse events and no AEs leading to treatment discontinuations or ICANS observed, with 40 percent of patients having no treatment-related AEs at all. Given the limited treatment options for mCRPC, these findings support further investigation of pasritamig and the role of KLK2-targeted T-cell therapies as a potential new approach for patients with aggressive disease." "Metastatic castration-resistant prostate cancer remains one of the most difficult stages of prostate cancer to treat, particularly for patients who haven't responded well to previous treatments," said Jeff Infante, M.D., Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. "This investigational approach underscores our commitment to developing innovative and practice-changing medicines that are well-tolerated and can be easily administered in community practice settings." The Phase 1 first-in-human study (NCT04898634) evaluated 174 patients with ages ranging from 36 to 89 years old and on average having received four prior therapies (range 1-13). The recommended phase 2 dose (RP2D) of pasritamig was 3.5mg on day 1, 18mg on day 8, 300mg intravenously on day 15 and then once every six weeks. The RP2D safety group also included patients treated once every three weeks as the toxicity profiles were very similar. The RP2D efficacy group only included patients treated at the RP2D once every six weeks.1 Within the RP2D safety group (n=45), treated once every three or six weeks, 100 percent had previously received androgen receptor pathway inhibitors, 75.6 percent had undergone taxane chemotherapy, and 37.8 percent had been treated with Lutetium 177 vipivotide tetraxetan prostate-specific membrane antigen radioligand therapy.1 The most common treatment- related adverse events (TRAEs) were Grade 1/2 infusion-related reactions (24.4 percent), Grade 1 cytokine release syndrome (CRS) presenting as fever only (8.9 percent, no steroid or tocilizumab was administered) and no reports of higher grade CRS. No TRAEs leading to treatment discontinuation or dose reduction were reported and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3 TRAEs were infrequent with 4.4 percent of patients reporting transient AST/ALT increases and neutropenia. There were no dose-limiting toxicities reported. The favorable safety profile of the RP2D regimen enabled convenient outpatient administration on a patient-friendly, once-every-six-weeks schedule.1 Of the patients in the RP2D efficacy group (n=33), treated once every six weeks, 42.4 percent achieved a 50 percent or greater reduction in their prostate-specific antigen (PSA) levels with a median rPFS of 7.9 months (95 percent confidence interval [CI] 2.9, not estimable [NE]) and 21.2 percent of patients continuing therapy. Treatment with pasritamig showed durable disease control and rPFS that compares favorably to historical data in heavily pretreated patients with mCRPC.1 Metastatic castration-resistant prostate cancer occurs in a significant portion of prostate cancer patients, with many progressing despite initial therapies.2 Overall survival from diagnosis of mCRPC patients ranges from 13.5 to 31.6 months, and lower in patients who have progressed on therapy.3 Treatment options remain limited, underscoring the urgent need for safer and more effective therapies.4 About Pasritamig (JNJ-78278343)Pasritamig (JNJ-78278343) is an investigational T-cell-engaging bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells and CD3 on T-cells. This approach is being evaluated in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a patient population with limited treatment options. About Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC) is a challenging and aggressive stage of prostate cancer where the disease progresses despite androgen deprivation therapy.2 Patients often experience metastasis to bones and lymph nodes, leading to poor outcomes and limited treatment options, including chemotherapy and second-line hormone therapies.5 The median overall survival ranges from 13.5 to 31.6 months depending on the site of metastasis, with a typical range of 15–36 months across the broader population.3,6 Survival rates can vary significantly depending on factors such as prior treatment history, disease burden, and response to therapy. The need for more effective treatments is critical, as the disease continues to impact a large number of men globally, with mCRPC being responsible for a substantial number of prostate cancer-related deaths. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of JNJ-78278343. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Source: Johnson & Johnson *Dr. Capucine Baldini has provided consulting, advisory, and speaking services to Johnson & Johnson; Dr. Baldini has not been paid for any media work. 1 Baldini, C., et al. Phase 1 Study Results of Pasritamig (JNJ-78278343) in Metastatic Castration-Resistant Prostate Cancer. 2025 American Society of Clinical Oncology Annual Meeting. June 2025.2 Scher, H. I., et al. (2016). "Treatment of castration-resistant prostate cancer: Current and future strategies." Nature Reviews Clinical Oncology, 13(10), 577-590.3 Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365-1374. doi:10.1007/s10552-021-01484-44 Ravi P, Mateo J, Lorente D, et al. Clinical prognostic factors and management of metastatic castration-resistant prostate cancer: a population-based study. PLoS One. 2015;10(10):e0139440. doi:10.1371/ Ryan, C. J., et al. (2015). "Abiraterone acetate in metastatic prostate cancer: A new era." Journal of Clinical Oncology, 33(10), 1051-1060.6 Kawahara, T., Saigusa, Y., Yoneyama, S. et al. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer 23, 214 (2023). Media contacts:Oncology Media Relations oncology_media_relations@ Investor contact:Lauren Johnsoninvestor-relations@ U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: SOURCE Johnson & Johnson Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Pan-Africanists Unite: Preparations Begin for 80th Anniversary of Historic Manchester Congress
ACCRA, Ghana, May 29, 2025 /PRNewswire/ -- The Pan-African Progressive Front (PPF), in collaboration with the Ghana Socialist Movement and Pan Africanism Today, convened a landmark online conference to initiate discussions and preparations for the upcoming 80th anniversary of the pivotal Fifth Pan-African Congress held in Manchester in 1945. Bringing together more than sixty influential pan-Africanists from 32 countries—including representatives from the USA and Brazil—the event underscored the enduring legacy and urgency of pan-African unity, decolonization, and the struggle against imperialism. The conference opened with Albie Walls of the All-African People's Revolutionary Party, who emphasized the far-reaching impact of the Manchester Congress on Africa's liberation movements and called for renewed clarity and action toward unifying progressive forces across the continent. Roland Diagne (FERNET, Senegal) highlighted the ongoing relevance of anti-neocolonial resolutions adopted at the Manchester Congress, noting the resurgence of patriotism and demands for true sovereignty, especially in the Sahel region. Diagne voiced concerns about external military interventions and stressed the need for ECOWAS to return to its foundational mission. Kwesi Pratt Jr., a journalist and member of the PPF organizing committee, presented a strategic roadmap for the anniversary celebration. He proposed the establishment of a central committee and specialized commissions on trade union issues, women's rights, and youth engagement, as well as mechanisms for mass mobilization and political power analysis. The meeting also featured voices from key organizations: Imani Na Umoja (African Party for the Independence of Guinea and Cape Verde) advocated for a comprehensive congress to unite organizations pursuing shared goals. Ouzayrou Mamane (Pan-African Movement for Reparations, Justice and Restoration of Historical Memory) insisted that reparations for former colonies are vital for economic independence and historical justice. Amina Hamani (MORFEPAN, Niger) urged transforming pan-Africanism from a symbol into an actionable tool for achieving full independence, amid renewed foreign interference. Saddam Alktif (CODESA) emphasized the unresolved crisis in Western Sahara, stating that pan-Africanism's objectives remain incomplete while occupation persists. Humphrey Quaye (PPF) reiterated the organization's commitment to fighting imperialism and neocolonialism, and called for collective action. Eighteen delegates contributed to a lively debate, culminating in Albie Walls' closing remarks and the formation of a central organizing committee. The PPF announced plans for further meetings and intensified coordination to ensure the 80th anniversary serves as a catalyst for real, unified progress in Africa's ongoing liberation and development. View original content: SOURCE Pan-African Progressive Front Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
20 hours ago
- Yahoo
Sanofi (ENXTPA:SAN) Reports Positive Phase 3 Results for Itepekimab in COPD Trial
Sanofi announced that its AERIFY-1 trial with Regeneron Pharmaceuticals successfully met its primary endpoint, indicating progress in COPD treatment. Despite this positive news, the company's share price fell 5% over the last week, contrasting with a 2% rise in the broader market. This decline may reflect investors' reactions to other company initiatives, such as its partnership with Stagecoach Performing Arts to raise awareness of autoimmune Type 1 diabetes. These positive developments, although promising, were not enough to counterbalance the broader market's upward trend, contributing weight against Sanofi's price movement. Buy, Hold or Sell Sanofi? View our complete analysis and fair value estimate and you decide. Uncover the next big thing with financially sound penny stocks that balance risk and reward. The recent successful completion of Sanofi's AERIFY-1 trial could have a positive impact on its revenue and earnings forecasts by strengthening its position in the COPD treatment market. However, despite these promising developments, the company's share price experienced a 5% decline in the past week, contrasting with the broader market's 2% rise. This movement might reflect investor reactions to other company initiatives, such as the partnership with Stagecoach Performing Arts, and broader market trends. Looking at a longer-term context, Sanofi's shares have delivered a total return of 19.59% over the past five years. Recent performance has exceeded the French Pharmaceuticals industry and market, which returned 4% and 4.5% declines respectively over the last year. Such outperformance indicates resilience amidst industry challenges and market volatility. Please consider the current share price of €95.9 against the consensus price target of €117.17, indicating a potential upside potential of approximately 18.5%. This price target is based on expectations of revenue reaching €51.2 billion and earnings of €10.2 billion by 2028, trading on a PE ratio of 16.1x. Analysts are assuming that Sanofi will enhance its growth trajectory driven by its innovative treatments and efficient operational strategies. Assess Sanofi's previous results with our detailed historical performance reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:SAN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@